Cepharanthine Blocks Presentation of Thyroid and Islet Peptides in a Novel Humanized Autoimmune Diabetes and Thyroiditis Mouse Model

Cheuk Wun Li, Roman Osman, Francesca Menconi, Larissa C. Faustino, Kookjoo Kim, Oliver B. Clarke, Hanxi Hou, Yaron TomerFrontiers in Immunology 2021 · DOI

Abstract

Autoimmune polyglandular syndrome type 3 variant (APS3v) refers to an autoimmune condition in which both type 1 diabetes (T1D) and autoimmune thyroiditis (AITD) develop in the same individual. HLA-DR3 confers the strongest susceptibility to APS3v. Previously we reported a unique amino acid signature pocket that predisposes to APS3v. We found that this pocket is flexible and can trigger APS3v by presenting both thyroid (Tg.1571, TPO.758) and islet (GAD.492) peptides to induce autoimmune response. We hypothesized that blocking the specific APS3v-HLA-DR3 pocket from presenting thyroid/islet antigens can block the autoimmune response in APS3v. To test this hypothesis we performed a virtual screen of small molecules blocking APS3v-HLA-DR3, and identified 11 small molecules hits that were predicted to block APS3v-HLA-DR3. Using the baculovirus-produced recombinant APS3v-HLA-DR3 protein we tested the 11 small molecules in an in vitro binding assay. We validated 4 small molecule hits, S9, S5, S53 and S15, that could block the APS3v-HLA-DR3 pocket in vitro. We then developed a novel humanized APS3v mouse model induced by co-immunizing a peptide mix of Tg.1571, TPO.758 and GAD.492. The immunized mice developed strong T-cell and antibody responses to the thyroid/islet peptides, as well as mouse thyroglobulin. In addition, the mice showed significantly lower free T4 levels compared to controls. Using the APS3v mouse model, we showed that one of the 4 small molecules, Cepharanthine (S53), blocked T-cell activation by thyroid/islet peptides ex vivo and in vivo. These findings suggested Cepharanthine may have a therapeutic potential in APS3v patients carrying the specific APS3v-HLA-DR3 pocket.

Introduction

Autoimmune diseases often occur concurrently in the same individual, a phenomenon exemplified by Autoimmune Polyglandular Syndrome type 3 variant (APS3v). Patients with APS3v suffer from both Type 1 Diabetes (T1D) and autoimmune thyroiditis (AITD). Genetic studies have identified the Human Leukocyte Antigen (HLA) system, specifically the HLA-DR3 molecule, as the primary susceptibility factor.

The mechanism involves a specific, flexible "pocket" within the HLA-DR3 molecule that is capable of presenting both thyroid-derived and pancreatic islet-derived peptides to T-cells. This "promiscuous" presentation triggers an autoimmune attack against multiple organs. Current clinical management focuses on hormone replacement therapy, which addresses symptoms but does not halt the underlying immune pathology. This study investigates a novel therapeutic strategy: using small molecules to block the pathogenic HLA-DR3 pocket and prevent the initiation of the autoimmune response.

Experimental Workflow and Methodology

The researchers developed a multi-stage pipeline to identify and validate potential inhibitors of the APS3v-HLA-DR3 pocket. This process integrated computational modeling, biochemical assays, and a novel animal model.

Figure 1: Experimental workflow for identifying and testing small molecule inhibitors of APS3v-HLA-DR3.

The study began with a virtual screening of 150,000 small molecules from the eMol library against a structural model of the APS3v-HLA-DR3 pocket. From this initial screen, 11 candidate molecules were selected for in vitro validation using ELISA-based binding assays with recombinant human APS3v-HLA-DR3 protein.

Validation of Small Molecule Inhibitors

Of the 11 initial candidates, four molecules—designated S9, S5, S15, and S53—demonstrated significant inhibitory activity. These molecules were further tested for their ability to block the binding of specific thyroid (Tg.1571, TPO.758) and islet (GAD.492) peptides.

Figure 5: Validation of the top four small molecule hits (S9, S5, S15, S53) in blocking the binding of thyroid (TPO.758, Tg.1571) and islet (GAD.492) peptides to APS3v-HLA-DR3.

Among these, Cepharanthine (S53), a plant-derived alkaloid, emerged as the most promising candidate. It showed robust, dose-dependent inhibition across all tested peptides, suggesting its potential as a broad-spectrum blocker for the APS3v-associated HLA pocket.

Development of a Humanized APS3v Mouse Model

To evaluate these inhibitors in a physiological context, the team engineered a novel humanized mouse model. These NOD-DR3 mice lack endogenous MHC molecules and instead express the human HLA-DR3 variant. By co-immunizing these mice with a cocktail of thyroid and islet peptides, the researchers successfully induced a state mimicking human APS3v. The mice exhibited high levels of autoantibodies and biochemical evidence of thyroid dysfunction, such as significantly reduced free T4 levels.

Therapeutic Efficacy of Cepharanthine

Cepharanthine (S53) was tested for its ability to suppress the autoimmune response in the humanized mouse model. Ex vivo analysis of T-cells from immunized mice showed that Cepharanthine treatment significantly reduced the production of inflammatory cytokines, including IFN-\gamma$ and IL-2. For instance, GAD.492-induced IFN-\gamma$ production was reduced from 56.3 pg/ml to 13.5 pg/ml. Subsequent in vivo trials confirmed that Cepharanthine effectively suppressed T-cell proliferation in response to both islet and thyroid antigens, demonstrating its potential to "quiet" the multi-organ autoimmune response.

Discussion and Clinical Implications

This study provides a proof-of-concept for antigen-specific immunotherapy in APS3v. By targeting the specific genetic "pocket" responsible for disease susceptibility, researchers can potentially suppress the autoimmune attack without the broad side effects associated with general immunosuppressants.

The identification of Cepharanthine is particularly significant, as it is already an approved drug in Japan for other indications, potentially accelerating its path to clinical trials for APS3v. Future research will focus on addressing the role of other HLA variants, such as DQ2 and DQ8, and evaluating the long-term histological impact of this treatment on thyroid and pancreatic tissues.

Summary updated

Abstract

Autoimmune polyglandular syndrome type 3 variant (APS3v) refers to an autoimmune condition in which both type 1 diabetes (T1D) and autoimmune thyroiditis (AITD) develop in the same individual. HLA-DR3 confers the strongest susceptibility to APS3v. Previously we reported a unique amino acid signature pocket that predisposes to APS3v. We found that this pocket is flexible and can trigger APS3v by presenting both thyroid (Tg.1571, TPO.758) and islet (GAD.492) peptides to induce autoimmune response. We hypothesized that blocking the specific APS3v-HLA-DR3 pocket from presenting thyroid/islet antigens can block the autoimmune response in APS3v. To test this hypothesis we performed a virtual screen of small molecules blocking APS3v-HLA-DR3, and identified 11 small molecules hits that were predicted to block APS3v-HLA-DR3. Using the baculovirus-produced recombinant APS3v-HLA-DR3 protein we tested the 11 small molecules in an <i>in vitro</i> binding assay. We validated 4 small molecule hits, S9, S5, S53 and S15, that could block the APS3v-HLA-DR3 pocket <i>in vitro</i>. We then developed a novel humanized APS3v mouse model induced by co-immunizing a peptide mix of Tg.1571, TPO.758 and GAD.492. The immunized mice developed strong T-cell and antibody responses to the thyroid/islet peptides, as well as mouse thyroglobulin. In addition, the mice showed significantly lower free T4 levels compared to controls. Using the APS3v mouse model, we showed that one of the 4 small molecules, Cepharanthine (S53), blocked T-cell activation by thyroid/islet peptides <i>ex vivo</i> and <i>in vivo</i>. These findings suggested Cepharanthine may have a therapeutic potential in APS3v patients carrying the specific APS3v-HLA-DR3 pocket.
BibTeX
@inproceedings{li2021cepharanthine,
  author = {Cheuk Wun Li and Roman Osman and Francesca Menconi and Larissa C. Faustino and Kookjoo Kim and Oliver B. Clarke and Hanxi Hou and Yaron Tomer},
  title = {{Cepharanthine Blocks Presentation of Thyroid and Islet Peptides in a Novel Humanized Autoimmune Diabetes and Thyroiditis Mouse Model}},
  booktitle = {Frontiers in Immunology},
  year = {2021},
  doi = {10.3389/fimmu.2021.796552},
}
Figure